Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$4.6 million.

  • Spyre Therapeutics' Cash from Financing Activities fell 136.33% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.8 million, marking a year-over-year decrease of 36.43%. This contributed to the annual value of $410.9 million for FY2024, which is 13.80% up from last year.
  • Spyre Therapeutics' Cash from Financing Activities amounted to -$4.6 million in Q3 2025, which was down 735.16% from $731,000 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Cash from Financing Activities ranged from a high of $225.6 million in Q4 2024 and a low of -$12.5 million during Q3 2023.
  • Its 3-year average for Cash from Financing Activities is $69.8 million, with a median of $731,000 in 2025.
  • Within the past 5 years, the most significant YoY rise in Spyre Therapeutics' Cash from Financing Activities was 2,045,175.00% (2023), while the steepest drop was 9,539.23% (2023).
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Cash from Financing Activities stood at $80,000 in 2021, then tumbled by 110.00% to -$8,000 in 2022, then skyrocketed by 2,045,175.00% to $163.6 million in 2023, then spiked by 37.89% to $225.6 million in 2024, then tumbled by 136.33% to -$4.6 million in 2025.
  • Its Cash from Financing Activities stands at -$4.6 million for Q3 2025, versus $731,000 for Q2 2025 and $125,000 for Q1 2025.